{"id":16984,"date":"2026-06-03T17:45:00","date_gmt":"2026-06-03T15:45:00","guid":{"rendered":"https:\/\/www.maunakeatech.com\/?p=16984"},"modified":"2026-06-03T17:23:22","modified_gmt":"2026-06-03T15:23:22","slug":"mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis","status":"publish","type":"post","link":"https:\/\/www.maunakeatech.com\/int\/news-int\/mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis\/","title":{"rendered":"Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying \u201cTriple Healing\u201d, a Cellvizio\u00ae\u2014 Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Colitis"},"content":{"rendered":"\n<p class=\"has-text-align-center\"><em>100% of patients achieving Cellvizio-assessed triple healing remained relapse-free over 24 months (0 of 29), versus a ~33% relapse rate among those who did not <\/em><\/p>\n\n\n\n<p class=\"has-text-align-center\"><em>A decade of converging, multi-center evidence positions Cellvizio as a differentiated tool to predict outcomes across inflammatory bowel disease (IBD), a therapeutic market with significant potential exceeding $25 billion<\/em><\/p>\n\n\n\n<p class=\"has-text-align-left\"><strong>Paris and Boston, June 3rd, 2026 \u2013 5:45 p.m. CEST \u2013 Mauna Kea Technologies (Euronext Growth: ALMKT)<\/strong>, inventor of Cellvizio<sup>\u00ae<\/sup>, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p\/nCLE) platform, today highlighted the publication of a prospective study in the United European Gastroenterology Journal (Minea et al.<sup>1<\/sup>) that strengthens the case for Cellvizio as a differentiated tool to predict relapse in ulcerative colitis (UC). The study introduces \u201ctriple healing\u201d as a new therapeutic target, adding to more than a decade of independent research pointing in the same clinical direction. <\/p>\n\n\n\n<p class=\"has-text-align-left\">The prospective study followed 81 UC patients in clinical and endoscopic remission over 24 months, with Cellvizio<sup>\u00ae<\/sup> assessment at baseline. Among them, 29 patients achieved \u201ctriple healing\u201d, defined as histological healing combined with intact intestinal permeability in both the terminal ileum and colon. None of these 29 patients relapsed during the 24-month follow-up, compared with a 33% relapse rate among those who did not reach this state. Assessed in vivo through probe-based confocal laser endomicroscopy, \u201ctriple healing\u201d represents a potential new therapeutic target that could refine ulcerative colitis management beyond conventional mucosal healing. <\/p>\n\n\n\n<p class=\"has-text-align-left\">This new publication is the latest in a consistent line of prospective studies, conducted across independent academic centers in Germany, the UK, Australia, France and Romania, all reaching a common conclusion: confocal endomicroscopic imaging of the intestinal barrier reflects disease outcomes more accurately than conventional endoscopy and\/or histology, across both ulcerative colitis and Crohn\u2019s disease.<\/p>\n\n\n\n<p>Together, this body of work, spanning more than 430 patients across independent cohorts in Mainz, Sydney, Erlangen and Ia\u0219i, establishes a reproducible scientific foundation. This accumulated peer-reviewed evidence base underpins Cellvizio\u2019s differentiated value proposition across the IBD market. <\/p>\n\n\n\n<p>Even with a therapeutic market exceeding $25 billion annually, roughly one in three IBD patients relapses despite apparent clinical remission, because conventional endoscopy cannot reliably detect the two drivers of relapse: residual microscopic inflammation and barrier dysfunction. Precise assessment of subclinical activity can help clinicians personalize treatment, avoid costly escalation to biologics, and identify at-risk patients earlier. Beyond clinical practice, this capability may also be of interest to therapeutic developers seeking precise endpoints for patient stratification, a potential avenue the Company intends to explore actively. <\/p>\n\n\n\n<p>Building on the reimbursement strategy that supported adoption in Barrett\u2019s Esophagus and pancreatic cyst diagnosis, where Cellvizio secured a dedicated CPT code, the Company intends to engage with medical societies and payers to explore a dedicated reimbursement pathway for IBD monitoring within an established, reimbursed therapeutic ecosystem.<\/p>\n\n\n\n<p><em>\u201cThis new study reinforces a decade of clinical evidence around Cellvizio-assessed barrier integrity in IBD: it predicts relapse and sustained remission more reliably than conventional endoscopy, histology or standard biomarkers. The fact that not a single one of the 29 patients achieving triple healing relapsed over 24 months is an outstanding result\u201d commented <\/em><strong>Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies<\/strong><em>. \u201cIBD has become one of the most dynamic markets in healthcare, but the bottleneck is no longer the availability of drugs, it is knowing whether a patient is truly in remission. That is exactly the question Cellvizio answers, and triple healing turns it into a concrete target clinicians can treat toward. Our priority now is to bring this advance into routine practice \u2014 including engaging payers on a dedicated reimbursement pathway \u2014 so that measuring deep, durable remission becomes the standard of care in IBD, with Cellvizio as its reference tool.\u201d<\/em><\/p>\n\n\n\n<p><sup>1<\/sup>Minea H. et al. Integrated Assessment of Intestinal Barrier Function and Microscopic Inflammation Using Confocal Laser Endomicroscopy for Relapse Prediction in Ulcerative Colitis. <a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ueg2.70181\">United European Gastroenterology Journal, 2026<\/a>.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.maunakeatech.com\/wp-content\/uploads\/2026\/06\/PR_ALMKT_UC_EN.pdf\">READ THE COMPLETE PRESS RELEASE<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>100% of patients achieving Cellvizio-assessed triple healing remained relapse-free over 24 months (0 of 29), versus a ~33% relapse rate among those who did not A decade of converging, multi-center evidence positions Cellvizio as a differentiated tool to predict outcomes across inflammatory bowel disease (IBD), a therapeutic market with significant potential exceeding $25 billion Paris [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":3334,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[34],"tags":[],"class_list":["post-16984","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-int"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying \u201cTriple Healing\u201d, a Cellvizio\u00ae\u2014 Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Colitis - Mauna Kea Technologies<\/title>\n<meta name=\"description\" content=\"Mauna Kea Technologies highlights the publication of a prospective study in the United European Gastroenterology Journal that strengthens the case for Cellvizio as a differentiated tool to predict relapse in ulcerative colitis (UC).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.maunakeatech.com\/news\/mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying \u201cTriple Healing\u201d, a Cellvizio\u00ae\u2014 Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Colitis - Mauna Kea Technologies\" \/>\n<meta property=\"og:description\" content=\"Mauna Kea Technologies highlights the publication of a prospective study in the United European Gastroenterology Journal that strengthens the case for Cellvizio as a differentiated tool to predict relapse in ulcerative colitis (UC).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.maunakeatech.com\/news\/mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis\/\" \/>\n<meta property=\"og:site_name\" content=\"Mauna Kea Technologies\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/maunakeatech\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-03T15:45:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.maunakeatech.com\/wp-content\/uploads\/2024\/08\/1320bd9d040fd78f3ce28aca98decf80d96c0c22.png\" \/>\n\t<meta property=\"og:image:width\" content=\"330\" \/>\n\t<meta property=\"og:image:height\" content=\"192\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Elizabeth\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@maunakeatech\" \/>\n<meta name=\"twitter:site\" content=\"@maunakeatech\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Elizabeth\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.maunakeatech.com\\\/news\\\/mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.maunakeatech.com\\\/news\\\/mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis\\\/\"},\"author\":{\"name\":\"Elizabeth\",\"@id\":\"https:\\\/\\\/www.maunakeatech.com\\\/#\\\/schema\\\/person\\\/46a359c122ceb464208dd447ff0dea82\"},\"headline\":\"Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying \u201cTriple Healing\u201d, a Cellvizio\u00ae\u2014 Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Colitis\",\"datePublished\":\"2026-06-03T15:45:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.maunakeatech.com\\\/news\\\/mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis\\\/\"},\"wordCount\":659,\"image\":{\"@id\":\"https:\\\/\\\/www.maunakeatech.com\\\/news\\\/mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.maunakeatech.com\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/1320bd9d040fd78f3ce28aca98decf80d96c0c22.png\",\"articleSection\":[\"News\"],\"inLanguage\":\"int\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.maunakeatech.com\\\/news\\\/mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis\\\/\",\"url\":\"https:\\\/\\\/www.maunakeatech.com\\\/news\\\/mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis\\\/\",\"name\":\"Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying \u201cTriple Healing\u201d, a Cellvizio\u00ae\u2014 Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Colitis - Mauna Kea Technologies\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.maunakeatech.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.maunakeatech.com\\\/news\\\/mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maunakeatech.com\\\/news\\\/mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.maunakeatech.com\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/1320bd9d040fd78f3ce28aca98decf80d96c0c22.png\",\"datePublished\":\"2026-06-03T15:45:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.maunakeatech.com\\\/#\\\/schema\\\/person\\\/46a359c122ceb464208dd447ff0dea82\"},\"description\":\"Mauna Kea Technologies highlights the publication of a prospective study in the United European Gastroenterology Journal that strengthens the case for Cellvizio as a differentiated tool to predict relapse in ulcerative colitis (UC).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.maunakeatech.com\\\/news\\\/mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis\\\/#breadcrumb\"},\"inLanguage\":\"int\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.maunakeatech.com\\\/news\\\/mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"int\",\"@id\":\"https:\\\/\\\/www.maunakeatech.com\\\/news\\\/mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.maunakeatech.com\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/1320bd9d040fd78f3ce28aca98decf80d96c0c22.png\",\"contentUrl\":\"https:\\\/\\\/www.maunakeatech.com\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/1320bd9d040fd78f3ce28aca98decf80d96c0c22.png\",\"width\":330,\"height\":192},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.maunakeatech.com\\\/news\\\/mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.maunakeatech.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying \u201cTriple Healing\u201d, a Cellvizio\u00ae\u2014 Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Colitis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.maunakeatech.com\\\/#website\",\"url\":\"https:\\\/\\\/www.maunakeatech.com\\\/\",\"name\":\"Mauna Kea Technologies\",\"description\":\"See Cells. Change Lives.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.maunakeatech.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"int\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.maunakeatech.com\\\/#\\\/schema\\\/person\\\/46a359c122ceb464208dd447ff0dea82\",\"name\":\"Elizabeth\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"int\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/753cb731fb04a2510df64185e7f61d3644390bc126783463265dfb2418e724d9?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/753cb731fb04a2510df64185e7f61d3644390bc126783463265dfb2418e724d9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/753cb731fb04a2510df64185e7f61d3644390bc126783463265dfb2418e724d9?s=96&d=mm&r=g\",\"caption\":\"Elizabeth\"},\"url\":\"https:\\\/\\\/www.maunakeatech.com\\\/int\\\/author\\\/elizabeth\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying \u201cTriple Healing\u201d, a Cellvizio\u00ae\u2014 Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Colitis - Mauna Kea Technologies","description":"Mauna Kea Technologies highlights the publication of a prospective study in the United European Gastroenterology Journal that strengthens the case for Cellvizio as a differentiated tool to predict relapse in ulcerative colitis (UC).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.maunakeatech.com\/news\/mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis\/","og_locale":"en_US","og_type":"article","og_title":"Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying \u201cTriple Healing\u201d, a Cellvizio\u00ae\u2014 Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Colitis - Mauna Kea Technologies","og_description":"Mauna Kea Technologies highlights the publication of a prospective study in the United European Gastroenterology Journal that strengthens the case for Cellvizio as a differentiated tool to predict relapse in ulcerative colitis (UC).","og_url":"https:\/\/www.maunakeatech.com\/news\/mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis\/","og_site_name":"Mauna Kea Technologies","article_publisher":"https:\/\/www.facebook.com\/maunakeatech\/","article_published_time":"2026-06-03T15:45:00+00:00","og_image":[{"width":330,"height":192,"url":"https:\/\/www.maunakeatech.com\/wp-content\/uploads\/2024\/08\/1320bd9d040fd78f3ce28aca98decf80d96c0c22.png","type":"image\/png"}],"author":"Elizabeth","twitter_card":"summary_large_image","twitter_creator":"@maunakeatech","twitter_site":"@maunakeatech","twitter_misc":{"Written by":"Elizabeth","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.maunakeatech.com\/news\/mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis\/#article","isPartOf":{"@id":"https:\/\/www.maunakeatech.com\/news\/mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis\/"},"author":{"name":"Elizabeth","@id":"https:\/\/www.maunakeatech.com\/#\/schema\/person\/46a359c122ceb464208dd447ff0dea82"},"headline":"Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying \u201cTriple Healing\u201d, a Cellvizio\u00ae\u2014 Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Colitis","datePublished":"2026-06-03T15:45:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.maunakeatech.com\/news\/mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis\/"},"wordCount":659,"image":{"@id":"https:\/\/www.maunakeatech.com\/news\/mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis\/#primaryimage"},"thumbnailUrl":"https:\/\/www.maunakeatech.com\/wp-content\/uploads\/2024\/08\/1320bd9d040fd78f3ce28aca98decf80d96c0c22.png","articleSection":["News"],"inLanguage":"int"},{"@type":"WebPage","@id":"https:\/\/www.maunakeatech.com\/news\/mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis\/","url":"https:\/\/www.maunakeatech.com\/news\/mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis\/","name":"Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying \u201cTriple Healing\u201d, a Cellvizio\u00ae\u2014 Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Colitis - Mauna Kea Technologies","isPartOf":{"@id":"https:\/\/www.maunakeatech.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.maunakeatech.com\/news\/mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis\/#primaryimage"},"image":{"@id":"https:\/\/www.maunakeatech.com\/news\/mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis\/#primaryimage"},"thumbnailUrl":"https:\/\/www.maunakeatech.com\/wp-content\/uploads\/2024\/08\/1320bd9d040fd78f3ce28aca98decf80d96c0c22.png","datePublished":"2026-06-03T15:45:00+00:00","author":{"@id":"https:\/\/www.maunakeatech.com\/#\/schema\/person\/46a359c122ceb464208dd447ff0dea82"},"description":"Mauna Kea Technologies highlights the publication of a prospective study in the United European Gastroenterology Journal that strengthens the case for Cellvizio as a differentiated tool to predict relapse in ulcerative colitis (UC).","breadcrumb":{"@id":"https:\/\/www.maunakeatech.com\/news\/mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis\/#breadcrumb"},"inLanguage":"int","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.maunakeatech.com\/news\/mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis\/"]}]},{"@type":"ImageObject","inLanguage":"int","@id":"https:\/\/www.maunakeatech.com\/news\/mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis\/#primaryimage","url":"https:\/\/www.maunakeatech.com\/wp-content\/uploads\/2024\/08\/1320bd9d040fd78f3ce28aca98decf80d96c0c22.png","contentUrl":"https:\/\/www.maunakeatech.com\/wp-content\/uploads\/2024\/08\/1320bd9d040fd78f3ce28aca98decf80d96c0c22.png","width":330,"height":192},{"@type":"BreadcrumbList","@id":"https:\/\/www.maunakeatech.com\/news\/mauna-kea-technologies-announces-new-publication-in-the-ueg-journal-identifying-triple-healing-a-cellvizio-assessed-therapeutic-target-associated-with-sustained-remis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.maunakeatech.com\/"},{"@type":"ListItem","position":2,"name":"Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying \u201cTriple Healing\u201d, a Cellvizio\u00ae\u2014 Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Colitis"}]},{"@type":"WebSite","@id":"https:\/\/www.maunakeatech.com\/#website","url":"https:\/\/www.maunakeatech.com\/","name":"Mauna Kea Technologies","description":"See Cells. Change Lives.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.maunakeatech.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"int"},{"@type":"Person","@id":"https:\/\/www.maunakeatech.com\/#\/schema\/person\/46a359c122ceb464208dd447ff0dea82","name":"Elizabeth","image":{"@type":"ImageObject","inLanguage":"int","@id":"https:\/\/secure.gravatar.com\/avatar\/753cb731fb04a2510df64185e7f61d3644390bc126783463265dfb2418e724d9?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/753cb731fb04a2510df64185e7f61d3644390bc126783463265dfb2418e724d9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/753cb731fb04a2510df64185e7f61d3644390bc126783463265dfb2418e724d9?s=96&d=mm&r=g","caption":"Elizabeth"},"url":"https:\/\/www.maunakeatech.com\/int\/author\/elizabeth\/"}]}},"_links":{"self":[{"href":"https:\/\/www.maunakeatech.com\/int\/wp-json\/wp\/v2\/posts\/16984","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maunakeatech.com\/int\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.maunakeatech.com\/int\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.maunakeatech.com\/int\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.maunakeatech.com\/int\/wp-json\/wp\/v2\/comments?post=16984"}],"version-history":[{"count":2,"href":"https:\/\/www.maunakeatech.com\/int\/wp-json\/wp\/v2\/posts\/16984\/revisions"}],"predecessor-version":[{"id":16989,"href":"https:\/\/www.maunakeatech.com\/int\/wp-json\/wp\/v2\/posts\/16984\/revisions\/16989"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.maunakeatech.com\/int\/wp-json\/wp\/v2\/media\/3334"}],"wp:attachment":[{"href":"https:\/\/www.maunakeatech.com\/int\/wp-json\/wp\/v2\/media?parent=16984"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.maunakeatech.com\/int\/wp-json\/wp\/v2\/categories?post=16984"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.maunakeatech.com\/int\/wp-json\/wp\/v2\/tags?post=16984"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}